A Multicenter, Open-label, Pilot Study of TAK-935 (OV935) in Patients With 15Q Duplication Syndrome or CDKL5 Deficiency Disorder (ARCADE Study)
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Soticlestat (Primary)
- Indications Epilepsy
- Focus Therapeutic Use
- Acronyms ARCADE Study
- Sponsors Takeda
- 27 Jun 2019 According to the Ovid Therapeutics media release, data from this trial is expected in the first quarter of 2020.
- 04 Jan 2019 According to an Ovid Therapeutics media release, the company plans to complete enrollment in this trial in the second half of 2019.
- 17 Dec 2018 According to the Ovid Therapeutics media release, the company will amend the protocols for this study to exclude patients being treated with perampanel and, in light of the mode of action of OV935, the duration of treatment will be extended with the potential to observe the extent of the effects of OV935 on seizure reduction over time.